Medadvisor share price rockets 28% higher on U.S. update

The Medadvisor Ltd (ASX:MDR) share price was one of the best performers on the Australian share market on Thursday…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medadvisor Ltd (ASX: MDR) share price was one of the best performers on the Australian share market on Thursday.

The digital medication management company's shares rocketed as much as 28% higher at one stage to a record high of 47.5 cents, before ending the day 23% higher at 45.5 cents.

Why did Medadvisor's shares rocket higher?

On Thursday Medadvisor announced that it has signed its second agreement in the United States. This agreement will see it provide medication education programs for a top 10 global pharmaceutical company through its strategic partner Adheris Health.

MedAdvisor is unable to name the pharmaceutical company, but it has been able to disclose its top 10 global status and that it has revenues in excess of US$20 billion.

According to the release, MedAdvisor will execute four pilot programs through a total of up to 4,000 U.S. pharmacies in partnership with Adheris Health.

The initial pilot phase will allow for program design, execution refinement and validation. After which, once the initial pilots have been successfully executed, management expects there to be an opportunity to increase their scale by adding additional pharmacies.

These initial pilot programs represent the first material revenue from its US expansion. The release explains that the gross revenue that will be recognised by MedAdvisor through the four pilot programs is expected to be A$825,000 over the next 12 months.

Management believes this is an important milestone in the commercialisation and scale of the US market opportunity.

What is MedAdvisor's Digital Health Programs platform?

The MedAdvisor Digital Health Programs platform interprets complex medication patterns, administers and curates health content in a compliant way, manages millions of patients uniquely, and renders and delivers messages optimised to each device so patients receive the right information at the right time.

In Australia, the company has worked with over 20 different Digital Health Program clients, including 8 of the top 10 Pharmaceutical companies, to fund digital and in-pharmacy programs designed to help patients take their medication safely, effectively and on time.

Management notes that the results of these programs have demonstrated significantly improved medication adherence.

MedAdvisor's CEO, Robert Read, was pleased with the development and sees a major opportunity in the U.S. market.

He said: "We have built a great platform to help people take their medication more effectively. The problems with non-adherence to medication in the US are estimated to cost 120,000 lives per annum."

"Strategically the US market is enormous and with our partnerships with Adheris and HMS, the opportunities to approach a very large addressable patient pool and generate revenue at scale over the next 3-5 years is significant. This second US agreement will generate estimated revenues of AU$800,000+ through a small subset of Adheris' total network is a preview of the scale that these partnerships can deliver," he concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended MedAdvisor. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »